Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies

Abstract

Aim: We examined the diagnostic accuracy of ultrasonography to detect any HS (defined as steatotic hepatocytes ≥ 5% on histology) and moderate-severe HS (defined as steatotic hepatocytes ≥ 30% on histology) by performing a systematic review and meta-analysis.

Methods: We systematically searched PubMed, Web of Science, and Scopus databases, from January 2011 to February 2021, to identify studies conducted in adults investigating the diagnostic accuracy of ultrasonography vs. histology for detecting either ≥ 5% histologically defined HS or moderate-severe HS (≥ 30%). Meta-analysis was performed using random-effects modeling.

Results: Twelve studies were included involving a total of 2921 individuals, 1710 (58.5%) of whom had HS ≥ 5% by histology. The overall sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of ultrasonography for the detection of ≥ 5% histologically defined HS, compared to histology, were 82% (95% confidence interval 76%-86%), 80% (72%-86%), 4.0 (2.90-5.70), and 0.23 (0.18-0.30), respectively. Based on the pooled analysis of seven studies, the overall sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of ultrasonography for the detection of ≥ 30% histologically defined HS were 85% (72%-92%), 85% (73%-93%), 5.72 (3.06-10.7), and 0.18 (0.10-0.33) , respectively. Funnel plots did not reveal any significant publication bias.

Conclusion: Conventional ultrasonography allows for reliable and accurate detection of ≥ 5% histologically defined HS compared to histology. These findings call for an extensive use of conventional ultrasonography in the clinical arena.

Keywords

Ultrasound / fatty liver / nonalcoholic fatty liver disease

References

[1] Bedossa P.Pathology of non-alcoholic fatty liver disease.Liver Int2017;37 Suppl 1:85-9

[2] Lonardo A.Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going?.Dig Dis1999;17:80-9

[3] AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions.Dig Liver Dis2017;49:471-83

[4] Mantovani A,Beatrice G.Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals.Gut2020;

[5] Mantovani A,Beatrice G.Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.Gut2020;

[6] Anstee QM,Tilg H.Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease.Nat Rev Gastroenterol Hepatol2018;15:425-39

[7] Lonardo A,Mantovani A.Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?.J Hepatol2018;68:335-52

[8] Mantovani A,Beatrice G.Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies.Gut2021;

[9] Valenti L.Redefining fatty liver disease classification in 2020.Liver Int2020;40:1016-7

[10] Bugianesi E,Cortez-Pinto H.How to diagnose NAFLD in 2016.J Hepatol2016;65:643-4

[11] Leoni S,Napoli L.Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis.World J Gastroenterol2018;24:3361-73 PMCID:PMC6092580

[12] Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.J Hepatol2016;64:1388-402

[13] Wong VW,Chitturi S.Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-Part 1: definition, risk factors and assessment.J Gastroenterol Hepatol2018;33:70-85

[14] Byrne CD,Scorletti E.Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults.BMJ2018;362:k2734

[15] Ballestri S,Lugari S.A critical appraisal of the use of ultrasound in hepatic steatosis.Expert Rev Gastroenterol Hepatol2019;13:667-81

[16] Hernaez R,Bonekamp S.Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis.Hepatology2011;54:1082-90 PMCID:PMC4197002

[17] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.J Hepatol2020;73:202-9

[18] Ballestri S,Baldelli E.Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases.Metabolism2017;72:57-65

[19] Stroup DF,Morton SC.Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group.JAMA2000;283:2008-12

[20] Cumpston M,Page MJ.Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions.Cochrane Database Syst Rev2019;10:ED000142

[21] Higgins JP.Quantifying heterogeneity in a meta-analysis.Stat Med2002;21:1539-58

[22] Deeks JJ,Irwig L.The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed.J Clin Epidemiol2005;58:882-93

[23] Fagan TJ.Letter: Nomogram for Bayes theorem.N Engl J Med1975;293:257

[24] van Werven JR,Nederveen AJ.Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy.Radiology2010;256:159-68

[25] Lee SS,Kim HJ.Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations.J Hepatol2010;52:579-85

[26] Wu J,Yerian L.Prevalence of liver steatosis and fibrosis and the diagnostic accuracy of ultrasound in bariatric surgery patients.Obes Surg2012;22:240-7

[27] Wang JH,Kuo FY.Ultrasonographic quantification of hepatic-renal echogenicity difference in hepatic steatosis diagnosis.Dig Dis Sci2013;58:2993-3000

[28] Sohail S,Mirza T.Ultrasound based evaluation of hepatic steatosis and fibrosis in hepatitis C non-responders.J Coll Physicians Surg Pak2013;23:548-52

[29] Macaluso FS,Camma C.Body mass index and liver stiffness affect accuracy of ultrasonography in detecting steatosis in patients with chronic hepatitis C virus genotype 1 infection.Clin Gastroenterol Hepatol2014;12:878-84. e1

[30] Bril F,Lomonaco R.Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients.Liver Int2015;35:2139-46

[31] Petrick A,Wood GC.Utility of ultrasound, transaminases, and visual inspection to assess nonalcoholic fatty liver disease in bariatric surgery patients.Obes Surg2015;25:2368-75 PMCID:PMC4917009

[32] Chen J,Wang M.Controlled attenuation parameter for the detection of hepatic steatosis in patients with chronic hepatitis B.Infect Dis (Lond)2016;48:670-5

[33] Kelly EM,Etheridge D.Sonography predicts liver steatosis in patients with chronic hepatitis B.J Ultrasound Med2017;36:925-32

[34] Petzold G,Ruhl J.Diagnostic accuracy of B-Mode ultrasound and Hepatorenal Index for graduation of hepatic steatosis in patients with chronic liver disease.PLoS One2020;15:e0231044 PMCID:PMC7194436

[35] Mantovani A,Mosca A.Complications, morbidity and mortality of nonalcoholic fatty liver disease.Metabolism2020;111S:154170

[36] Simon TG,Khalili H.Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.Gut2020; PMCID:PMC8185553

[37] Nasr P,Ekstedt M.The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease.Liver Int2020;40:1069-78

[38] Byrne CD.Time to replace assessment of liver histology with MR-based imaging tests to assess efficacy of interventions for nonalcoholic fatty liver disease.Gastroenterology2016;150:7-10

[39] Ajmera V,Caussy C.Magnetic resonance imaging proton density fat fraction associates with progression of fibrosis in patients with nonalcoholic fatty liver disease.Gastroenterology2018;155:307-10. e2 PMCID:PMC6090543

[40] Caussy C,Sirlin CB.Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials.Hepatology2018;68:763-72 PMCID:PMC6054824

[41] Pelusi S.Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease.Liver Int2019;39:250-6

[42] Keating SE,Parker HM.Effect of aerobic exercise training dose on liver fat and visceral adiposity.J Hepatol2015;63:174-82

[43] Sung KC,Lee JY.Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver.J Hepatol2016;65:791-7

[44] Kim W,Lee JS.Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease.Aliment Pharmacol Ther2017;45:1073-83

[45] Kotler DP,Engelson ES.The effect of recombinant human growth hormone with or without rosiglitazone on hepatic fat content in HIV-1-infected individuals: a randomized clinical trial.Antivir Ther2016;21:107-16 PMCID:PMC5110034

[46] Eriksson JW,Jansson PA.Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.Diabetologia2018;61:1923-34 PMCID:PMC6096619

[47] Harrison SA,Abdelmalek MF.NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.Lancet2018;391:1174-85

[48] Ballestri S,Baldelli E.Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease.Diagnostics (Basel)2021;11:98 PMCID:PMC7827076

[49] Tarantino G,Balsano C.Liver-spleen axis in nonalcoholic fatty liver disease.Expert Rev Gastroenterol Hepatol2021;15:759-69

[50] Xu L,Li P,Mi YQ.A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B.Dig Liver Dis2017;49:910-7

[51] García-Monzón C,Porrero JL.Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones.Liver Int2015;35:1983-91

[52] Nelson SM,Lisanti C.Ultrasound fatty liver indicator: a simple tool for differentiating steatosis from nonalcoholic steatohepatitis: validity in the average obese population.J Ultrasound Med2020;39:749-59

[53] Loy M,Chessa L.The prevalence of bright liver echo pattern in patients with chronic hepatitis C: correlation with steatosis and fibrosis.J Ultrasound2016;19:91-8 PMCID:PMC4879006